A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

INTRODUCTION: Bevacizumab and gemcitabine are key drugs for treating recurrent epithelial ovarian cancer. However, information about the combination of bevacizumab and gemcitabine is insufficient. We conducted a phase II study to assess the feasibility, clinical activity, and toxicity of this combin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Ovarian Res
Main Authors: Nagao, Shoji, Kogiku, Ai, Suzuki, Kazuhiro, Shibutani, Takashi, Yamamoto, Kasumi, Jimi, Tomoatsu, Kitai, Miho, Shiozaki, Takaya, Matsuoka, Kazuko, Yamaguchi, Satoshi
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006142/
https://ncbi.nlm.nih.gov/pubmed/32028974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-020-0617-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados